JP2716565B2 - 新規リポポリアミン、その製造方法及び利用 - Google Patents
新規リポポリアミン、その製造方法及び利用Info
- Publication number
- JP2716565B2 JP2716565B2 JP2099472A JP9947290A JP2716565B2 JP 2716565 B2 JP2716565 B2 JP 2716565B2 JP 2099472 A JP2099472 A JP 2099472A JP 9947290 A JP9947290 A JP 9947290A JP 2716565 B2 JP2716565 B2 JP 2716565B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- hydrogen
- integer
- lipopolyamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 239000012634 fragment Substances 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 125000001931 aliphatic group Chemical group 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- -1 N-hydroxysuccinamide ester Chemical class 0.000 claims description 12
- 238000001890 transfection Methods 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000006242 amine protecting group Chemical group 0.000 claims description 5
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- HKUFIYBZNQSHQS-UHFFFAOYSA-N n-octadecyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC HKUFIYBZNQSHQS-UHFFFAOYSA-N 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims 1
- 229910000071 diazene Inorganic materials 0.000 claims 1
- 150000001412 amines Chemical group 0.000 abstract description 7
- ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical group [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 6
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- NMAKWCABHXLADB-UHFFFAOYSA-N 2-amino-n,n-dioctadecylacetamide Chemical compound CCCCCCCCCCCCCCCCCCN(C(=O)CN)CCCCCCCCCCCCCCCCCC NMAKWCABHXLADB-UHFFFAOYSA-N 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 229940063675 spermine Drugs 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- LHFNPUGRSYOPLF-UHFFFAOYSA-N (4-nitrophenyl) 2-(phenylmethoxycarbonylamino)acetate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)CNC(=O)OCC1=CC=CC=C1 LHFNPUGRSYOPLF-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000008125 glucin Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003574 melanophore Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Description
用に関する。
基 (R1及びR2=各々12ないし22炭素原子を含む脂肪族基;
R′=水素又は随時フェノールで置換されたアルキ
ル)、又は基 (X=CH2又はCO;R3及びR4=各々11ないし21炭素原子を
含む脂肪族基)を表す、のリポポリアミンに関し、それ
らの塩は、真核細胞のトランスフェクションのベクター
として有用である。
式: のリポポリアミン及びそれらの塩を提供し、 式中、 −nは、1〜5の整数であり、 −mは、2〜6の整数であり、nが2〜5の場合、夫々
のフラグメント は同一又は異なってよく、 −基Rの一つかつ一つだけは下記式: 式中、R1及びR2は、同一又は異なっていてもよく、各々
飽和脂肪族基CpH2p+2又は不飽和脂肪族基CpH2p又はCpH
2p-2を表し、pは12〜22の整数であり、及びR′は水素
又はフェニルにより置換され又は置換されていない1〜
4炭素原子のアルキルである、 の基、又は下記式: 式中、Xはメチレン基(−CH2−)又はカルボニル基
(−CO−)を表し、R3及びR4は、同一又は異なっていて
よく、各々飽和脂肪族基Cp′H2p′+2又は不飽和脂肪族
基Cp′H2p′又はCp′H2p′-2を表し、p′は11〜21の整
数であり、及び他の基Rは水素を表す、 の基を表す。
り、mが3又は4であり、フラグメント におけるmの値が同一又は異なっており、 及びRは: R1及びR2の各々が12〜22炭素原子を含むアルキル基を表
し、及びR′が水素原子を表す式(II)の基か、又はR3
−X−及びR4−X−の各々が12〜22炭素原子を含むアル
カノイル基を表す式(III)の基を表す化合物、及びそ
れらの塩である。
グルシンジオクタデシルアミド(DOGS)及びジパルミト
イルホスファチジル−エタノールアミン5−カルボキシ
スペルミルアミド(DPPES)である。
は、下記式: 式中、m及びnは上に定義した通りであり、基R5の中の
一つかつ一つだけはカルボキシル基であり、そして他の
基R5は水素を表し、及びZはアミン保護基を表す、 の化合物を、下記式: 式中、R1、R2及びR′は上に定義した通りである、 の化合物、或いは、下記式: 式中、R3、R4及びXは上に定義した通りである、 の化合物のいずれかとを反応させ、その後に保護基Zを
水素で置換することにより得られる。
合は、ジシクロヘキシルカルボジイミドのようなジミイ
ドの存在において縮合反応を行い、塩化メチレンのよう
なハロゲン化脂肪族系溶剤から選択された不活性有機溶
剤中で処理することが特に有利である。
合は、式(VI)の化合物との縮合反応を行う前に、ジシ
クロヘキシル ジカルボジイミドのようなイミドの存在
において、ハロゲン化脂肪族炭化水素(塩化メチレンの
ような)及びエーテル(例えばテトラヒドロフラン)か
ら選択された有機溶剤中で、予めN−ヒドロキシスクシ
ンイミドで式(IV)の生成物の酸官能基を処理すること
が特に有利である。生成した混合エステルの式(VI)の
化合物との縮合反応は、一般にトリエチルアミンのよう
な有機塩基の存在において、有機溶剤(例えばクロロホ
ルム又はエタノール)中で30ないし50℃の間の温度で行
われる。
容易に置換される保護基Zが一般に使用される。保護基
として、酸(トリフルオロ酢酸)の水素原子によって容
易に置換されるt−ブトキシカルボニル基を使用するこ
とが特に有利である。
らシアノアルキル化及び続いてのニトリル官能基のアミ
ン官能基への還元により得ることができ、それによりア
ミン官能基の保護が得られる。
を、下記式: 式中、R′は上に定義した通りであり、アミン官能基は
保護されており、酸官能基は活性当されている、 のアミノ酸と反応させることにより得ることができる。
パラジウムのような触媒の存在における水素化分解によ
り容易に水素で置換される、ベンジルカルボニル基によ
ってアミン官能基を保護することが特に有利である。酸
官能基は一般にp−ニトロフェニルエステルに転換する
ことによって活性化される。
ある。
性媒体中で不安定であり、その陽イオン性部分によって
プラスミド又はオリゴヌクレオチドDNAと強く会合して
後者を密集させ且つ脂質層で覆う、単層状の微小粒子を
形成する性質を有する。核酸に比較して過剰の陽イオン
荷電を使用することによって、脂質/DNA複合体は細胞膜
上に吸着され、それにより細胞によるDNAの吸収を容易
にするのであろう。
又は初代培養)のトランスフェクションを行う際に大き
い効果を有する特異的な、無毒性の、生物分解性のベク
ターを構成する。
清の不存在下において細胞懸濁液を、使用時に適当な媒
体中の式(I)のリポポリアミンの溶液とDNAの溶液と
から得られるトランスフェクト混合物と接触させること
により行われる。
し、DNAに関して過剰(2ないし5倍)の電荷量のリポ
ポリアミンを使用することが特に有利である。
く、10分間及び48時間の間であることができる。
を最適化又は改変する必要なく、様々な起源(例えば、
LMKT、Ras4、CHO、F9、Bu4、S49、Hela及びAtT20を含
む)の細胞系統並びに初代細胞に適用できる利点を有す
る。
法(燐酸カルシウム共沈降法又はデキストラン法)の適
用によりトランスフェクトすることが不可能であった脆
弱な細胞(脳下垂体中間又は前葉細胞、クロム親和細
胞、末梢又は中枢ニューロン)にトランスフェクトする
ことを可能とするものである。
ランスフェクトされた細胞に対して毒性を呈さない。そ
れらは脳間又は全身的な注射後、ラットに急性毒性を示
さない。
めに有用である式(I)のリポポリアミンの安定なアル
コール性又は水性溶液を提供する。約50回のトランスフ
ェクションを行うことができる、1mg/mlを含む溶液が一
般に調製される。
ある。
(t−ブトキシカルボニル)スペルミン(1半量)及び
グリシンジオクタデシルアミド(1当量)の混合物を、
ジシクロヘキシルカルボジイミド(1.1当量)の存在に
おいて12時間撹拌する。
キシ−カルボニル)−5−カルボキシスペルミルグリシ
ンジオクタデシルアミドが90%の収率で得られ、その生
成物の保護基は、約20℃の温度で10分間トリフルオロ酢
酸で処理することにより除去される。それにより、5−
カルボキシスペルミルグリシンジオクイタデシルアミド
(DOGS)のテトラキス(トリフルオロ酢酸塩)が得られ
る。
中で200MHzでのプロトン核磁気共鳴スペクトルによって
確認される(化学シフトδはppmで示される):0.9
[t、(CH3)2];1.3[m、2×(CH2)15];1.4−1.
7(m、2×CH2CH2NCO);1.8−2.2(m、4×CH2CH
2N+);3.0−3.2(m、5×CH2N+);3.55(t、2×CH2N
CO);4.0(t、CHN+);4.15(s、COCH2ND)。
ル)スペルミンは下記の方法で調製することができる: ジメチルホルムアミドに溶かしたL−オルニチンの1M
溶液に、2.2当量のアクリロニトリルを添加する。混合
物を約20℃の温度で1時間撹拌する。
存在において水素で還元し、エタノール性水酸化カリウ
ムの存在において処理すると、L−5−カルボキシスペ
ルミンが得られ、そのアミン官能基は常法によりt−ブ
トキシカルボニル基により保護される。
(1.1当量)の存在において塩化メチレン中で5時間処
理することにより、ジオクタデシルアミン(1当量)と
N−カルボベンゾキシグリシンp−ニトロフェニルエス
テル(1当量)の縮合によって調製できる。
て1時間水素化後、塩化メチレン/エタノール混合物中
で処理すると、グリシンジオクタデシルアミドが87%の
収率で得られる。
ル)スペルミン(1当量)をジシクロヘキシルカルボジ
イミド(1.1当量)の存在においてN−ヒドロキシスク
シンイミド(1.1当量)と12時間反応させ、塩化メチレ
ン/テトラヒドロフラン混合物中で処理する。
存在において、クロロホルム/エタノール混合物中でジ
パルミトイルホスファチジルエタノールアミン(1当
量)で40℃において12時間処理する。反応混合物の処理
後、ジパルミトイルホスファチジルエタノールアミンテ
トラ(t−ブトキシカルボニル)−5−カルボキシスペ
ルミルアミドが55%の収率で得られ、その生成物の保護
基を塩化メチレン中でトリフルオロ酢酸で除去する。そ
れにより、ジパルミトイルホスファチジルエタノールア
ミン5−カルボキシスペルミルアミド(DPPES)がテト
ラキス(トリフルオロ酢酸塩)の形で得られる。
/重水素化されたメタノール混合物(容積比1:1)中で2
00MHzでのプロトン核磁気共鳴スペクトルによって確認
される(化学シフトδはppmで示される):0.85[t、
(CH3)2];[m、2×(CH2)12];1.5−1.65[m、
2×CH2CO2);1.8−2.1(m、4×CH2CH2N+);2.3(t
t、2×CH2CH2CO2)2.9−3.1(モル、5×CH2N+);3.2
(bm、CH2NDCO);3.75−4.05(m、CHN+、2×CH2OP);
4.15−4.40(2×dd、CO2CH2);5.20(OCH)。
に希釈して、2mMの溶液とする。この溶液7.5μを取り
出し、250μのDMEM培地(ダルベッコ[Dulbecco]改
質必須培地[Essential Medium])で希釈する。
セチルトランスフェラーゼ(CAT)の発現のためのベク
ターを含むプラスミド5μgを含む溶液を調製する(例
えばAPl配列[“結合コンセンサス配列(binding conse
nsus sequence)”(pCAT 4XB)]の4コピーを含むフ
ラグメント(BamH I−Xba I)の挿入により、プラスミ
ドpCAT8+[L.Klein−Hitpass等、Cell、46、1053−106
1(1986)]から誘導された構成物)。
euroscience、17、1275−1285(1986)に従って調製さ
れた]の懸濁液を血清の不存在下に500μのDMEM培地
中に調製する。
混合物を細胞懸濁液に添加する。
平板培養する。48時間後、細胞を燐酸塩緩衝液(PBS)
で洗浄し、次いでC.M.Gorman等、Mol.Cell.Biol.、2、
1044−1051(1982)の方法に従ってクロラムフェニコー
ル アセチルトランスフェラーゼ活性を測定する。
中に再分散する。数回冷却/加熱サイクルを行った後、
50μの上澄液を14Cで標識したクロラムフェニコール
(0.1μCi)を含む40μのトリス−HCl(pH7.4)に添
加する。37℃で5分間後、20μのアセチル−COA(4m
M)を添加することによって反応を開始する。37℃で1
時間後、クロラムフェニコールとそのアセチル化誘導体
を酢酸エチルで抽出し、薄層クロマトグラフィーにより
分離し、及びオートラジオグラフを行う。オートラジグ
ラムは適当な方法により分析する。
ロモーターを分析することを可能とする方法である。
々のフラグメント、 は同一又は異なってよく、 −基Rの一つかつ一つだけは下記式: 式中、R1及びR2は、同一又は異なっていてもよく、飽和
脂肪族基CpH2p+2又は不飽和脂肪族基CpH2p又はCpH2p-2
を表し、pは12〜22の整数であり、及びR′は水素又は
フェニルにより置換され又は置換されていない1〜4炭
素原子のアルキルである、 の基、又は下記式: 式中、Xはメチレン基(−CH2−)又はカルボニル基
(−CO−)を表し、R3及びR4は、同一又は異なっていて
もよく、各々飽和脂肪族基Cp′H2p′又は不飽和脂肪
族基Cp′H2p′+2又はCp′,H2p′−2を表し、
p′は11〜21の整数であり、及び他の基Rは水素を表
す、 の基を表す、D、L又はDL形の、リポポリアミン及びそ
の塩。
し、及びR′が水素原子を表す式(II)の基か、又はR3
−X−及びR4−X−の各々が12〜22炭素原子を含むアル
カノイル基のいずれかを表す式(III)の基を表す、上
記1に記載のリポポリアミン、及びその塩。
アミドである、上記1に記載のリポポリアミン。
カルボキシスペルミルアミドである、上記1に記載のリ
ポポリアミン。
の中の一つかつ一つだけはカルボキシル基であり、そし
て他の基R5は水素を表し、及びZはアミン保護基を表
す、 の化合物とジミイドの存在において、ハロゲン化脂肪族
系溶剤から選択された不活性有機溶剤中で反応させ、保
護基Zを水素で置換し、得られた生成物を臨時塩の形態
で単離することを特徴とする、Rが式(II)の基を表す
上記1に記載のリポポリアミンの製造方法。
の中の一つかつ一つだけはカルボキシル基であり、そし
て他の基R5は水素を表し、及びZはアミン保護基を表
す、 の化合物のN−ヒドロキシスクシンアミドエステルと、
第三アミン塩の存在において、アルコール及びハロゲン
化脂肪炭化水素から選択された不活性有機溶剤中で反応
させ、保護基Zを水素で置換し、得られた生成物を臨時
塩の形態で単離することを特徴とする、Rが式(III)
の基を表す上記1に記載のリポポリアミンの製造方法。
リポポリアミンとプラスミド又はオリゴヌクレオチドDN
Aの混合物を形成し、及びこのトランスフェクト混合物
をトランスフェクトされる細胞の懸濁物と接触させるこ
とを特徴とする、真核細胞のトランスフェクションの方
法。
記7に記載の方法。
ンの水及び/又はエタノール溶液を含有して成る、真核
細胞のトランスフェクション用の組成物。
Claims (5)
- 【請求項1】下記式: 上式中、 −nは1〜5の整数であり、 −mは2〜6の整数であり、nが2ないし5の場合、夫
々のフラグメント は同一又は異なってよく、 −基Rの一つかつ一つだけは下記式: 式中、R1及びR2は、同一又は異なっていてもよく、各々
飽和脂肪族基CpH2p+2又は不飽和脂肪族基CpH2p又はCpH
2p-2を表し、pは12〜22の整数であり、及びR′は水素
又はフェニルにより置換され又は置換されていない1な
いし4炭素原子のアルキルである、 の基、又は下記式: 式中、Xはメチレン基(−CH2−)又はカルボニル基
(−CO−)を表し、R3及びR4は、同一又は異なっていて
もよく、各々飽和脂肪族基Cp′H2p′+2又は不飽和
脂肪族基Cp′H2p′又はCp′H2p′−2を表し、
p′は11〜21の整数であり、及び他の基Rは水素を表
す、 の残基を表す、D、L又はDL形の、リポポリアミン及び
その塩。 - 【請求項2】5−カルボキシスペルミルグリシンジオク
タデシルアミドである特許請求の範囲第1項に記載のリ
ポポオリアミン。 - 【請求項3】下記式: 式中、R1、R2及びR′は特許請求の範囲1項記載に定義
された通りである、 の化合物を 下記式: 式中、m及びnは特許請求の範囲1項に定義された通り
であり、基R5の中の一つかつ一つだけはカルボキシル基
であり、そして他の基R5は水素を表し、及びZはアミン
保護基を表す、の化合物とジイミドの存在において、ハ
ロゲン化脂肪族系溶剤から選択された不活性有機溶剤中
で反応させ、保護基Zを水素で置換し、得られた生成物
を臨時塩の形態で単離することを特徴とする、Rが式
(II)の基を表す特許請求の範囲1項に記載のリポポリ
アミンの製造方法。 - 【請求項4】下記式: 式中、R3、R4及びXは特許請求の範囲1項に定義された
通りである、 の化合物を、 下記式: 式中、m及びnは特許請求の範囲1項に定義された通り
であり、基はR5の中の一つかつ一つだけはカルボキシル
基であり、そして他の基R5は水素を表し、及びZはアミ
ン保護基を表す、の化合物のN−ヒドロキシスクシンア
ミドエステルと、第三アミン塩の存在において、アルコ
ール及びハロゲン化脂肪炭化水素から選択された不活性
有機溶剤中で反応させ、保護基Zを水素で置換し、得ら
れた生成物を随時塩の形態で単離することを特徴とす
る、Rが式(III)の基を表す特許請求の範囲1項に記
載のリポポリアミンの製造方法。 - 【請求項5】適当な媒体中で、特許請求の範囲1項に記
載のリポポリアミンとプラスミド又はオリゴヌクレオチ
ドDNAの混合物を形成し、及びこのトランスフェクト混
合物をトランスフェクトされる細胞の懸濁物と接触させ
ることを特徴とする、真核細胞のトランスフェクション
の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR898905037A FR2645866B1 (fr) | 1989-04-17 | 1989-04-17 | Nouvelles lipopolyamines, leur preparation et leur emploi |
FR8905037 | 1989-04-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02292246A JPH02292246A (ja) | 1990-12-03 |
JP2716565B2 true JP2716565B2 (ja) | 1998-02-18 |
Family
ID=9380787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2099472A Expired - Lifetime JP2716565B2 (ja) | 1989-04-17 | 1990-04-17 | 新規リポポリアミン、その製造方法及び利用 |
Country Status (11)
Country | Link |
---|---|
US (3) | US5171678A (ja) |
EP (1) | EP0394111B1 (ja) |
JP (1) | JP2716565B2 (ja) |
AT (1) | ATE154035T1 (ja) |
CA (1) | CA2014518C (ja) |
DE (1) | DE69030839T2 (ja) |
DK (1) | DK0394111T3 (ja) |
ES (1) | ES2104593T3 (ja) |
FR (1) | FR2645866B1 (ja) |
GR (1) | GR3023691T3 (ja) |
IL (1) | IL94077A (ja) |
Families Citing this family (350)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2645866B1 (fr) * | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
US6509032B1 (en) | 1991-08-28 | 2003-01-21 | Mcmaster University | Cationic amphiphiles |
US5175103A (en) * | 1991-10-21 | 1992-12-29 | Trustees Of University Of Pennsylvania | Preparation of pure cultures of post-mitotic human neurons |
ATE260679T1 (de) * | 1992-04-03 | 2004-03-15 | Univ California | Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5329029A (en) * | 1992-11-05 | 1994-07-12 | Wan Barbara Y | Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates |
EP1624068A1 (en) * | 1993-06-01 | 2006-02-08 | Life Technologies Inc. | Genetic immunization with cationic lipids |
US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
FR2714830B1 (fr) * | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
US6075012A (en) * | 1994-02-11 | 2000-06-13 | Life Technologies, Inc. | Reagents for intracellular delivery of macromolecules |
US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
US5651981A (en) * | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
US5858140A (en) * | 1994-07-22 | 1999-01-12 | Minnesota Mining And Manufacturing Company | Nonwoven surface finishing articles reinforced with a polymer backing layer and method of making same |
US5908635A (en) * | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
US5892071A (en) * | 1994-09-30 | 1999-04-06 | The Reagents Of The University Of California | Cationic transport reagents |
US5527928A (en) * | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
CA2200952C (en) * | 1994-09-30 | 2006-04-11 | Inex Pharmaceuticals Corp. | Novel compositions comprising quaternary ammonium compounds and neutral lipids for the introduction of polyanionic materials into cells |
US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
DK0782862T3 (da) * | 1994-10-14 | 2005-01-03 | Daiichi Seiyaku Co | Sammensætning indeholdende genetisk materiale |
FR2727679B1 (fr) * | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
US5840710A (en) * | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US5747471A (en) * | 1994-12-09 | 1998-05-05 | Genzyme Corporation | Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules |
US5650096A (en) * | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US6071890A (en) * | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US6383814B1 (en) | 1994-12-09 | 2002-05-07 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5767099A (en) * | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
US5948767A (en) * | 1994-12-09 | 1999-09-07 | Genzyme Corporation | Cationic amphiphile/DNA complexes |
US5719131A (en) * | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
US5910487A (en) * | 1994-12-09 | 1999-06-08 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
US6331524B1 (en) | 1994-12-09 | 2001-12-18 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy |
US6630455B1 (en) | 1995-01-13 | 2003-10-07 | Vanderbilt University | Methods for inducing mucosal immune responses |
FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
IL122290A0 (en) * | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
CA2223088A1 (en) | 1995-06-07 | 1996-12-19 | Bob Dale Brown | Novel carbamate-based cationic lipids |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
WO1996040725A1 (en) | 1995-06-07 | 1996-12-19 | Genta Incorporated | Phosphonic acid-based cationic lipids |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
JPH11510489A (ja) * | 1995-07-21 | 1999-09-14 | ジンタ・インコーポレイテッド | 新規アミド基本カチオン性脂質 |
US6339173B1 (en) | 1996-07-22 | 2002-01-15 | Promega Biosciences, Inc. | Amide-based cationic lipids |
US5869715A (en) * | 1995-09-27 | 1999-02-09 | The Reagents Of The University Of California | Polyfunctional cationic cytofectins |
FR2739292B1 (fr) * | 1995-09-28 | 1997-10-31 | Rhone Poulenc Rorer Sa | Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations |
FR2741066B1 (fr) * | 1995-11-14 | 1997-12-12 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
US6228391B1 (en) | 1996-05-02 | 2001-05-08 | Terumo Kabushiki Kaisha | Amidine derivatives and drug carriers comprising the same |
US5935936A (en) * | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
US6093816A (en) * | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
FR2754828B1 (fr) * | 1996-10-23 | 1998-12-24 | Univ Toulouse | Structure membranaire artificielle, procede et polymere pour sa preparation, procede de preparation de ce polymere, particule et film comprenant cette structure |
CA2271325A1 (en) | 1996-11-12 | 1998-05-22 | The Regents Of The University Of California | Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
US5877220A (en) * | 1997-03-06 | 1999-03-02 | Genta, Incorporated | Amide-based oligomeric cationic lipids |
US6034135A (en) * | 1997-03-06 | 2000-03-07 | Promega Biosciences, Inc. | Dimeric cationic lipids |
US5925628A (en) * | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5912239A (en) * | 1997-04-04 | 1999-06-15 | Genzyme Corporation | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5948925A (en) * | 1997-05-06 | 1999-09-07 | Genzyme Corporation | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids |
US5952516A (en) * | 1997-05-08 | 1999-09-14 | Genzyme Corporation | Cationic amphiphiles containing multiplesteroid lipophilic groups |
US5942634A (en) * | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
US20030073640A1 (en) * | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
AU745958B2 (en) * | 1997-08-13 | 2002-04-11 | Biontex Laboratories Gmbh | Novel lipopolyamines, and the preparation and use thereof |
US5998482A (en) * | 1997-11-10 | 1999-12-07 | David; Sunil A. | Use of synthetic polycationic amphiphilic substances with fatty acid or hydrocarbon substituents as anti-sepsis agents |
GB9726073D0 (en) | 1997-12-09 | 1998-02-04 | Smithkline Beecham Plc | Novel compounds |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
ATE306556T1 (de) | 1998-01-30 | 2005-10-15 | Aventis Pharma Sa | Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung. |
FR2777017B1 (fr) * | 1998-04-02 | 2002-08-23 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications |
IL138625A0 (en) * | 1998-04-02 | 2001-10-31 | Aventis Pharma Sa | Novel nucleic acid transfer agents, compositions containing same and uses |
WO2000012454A1 (en) * | 1998-08-27 | 2000-03-09 | Alberto Haces | Novel polycationic lipids |
EP1129064B1 (en) | 1998-11-12 | 2008-01-09 | Invitrogen Corporation | Transfection reagents |
US6770740B1 (en) | 1999-07-13 | 2004-08-03 | The Regents Of The University Of Michigan | Crosslinked DNA condensate compositions and gene delivery methods |
US8143195B2 (en) * | 2000-01-24 | 2012-03-27 | Yingjian Wang | Arrays for bringing two or more reagents in contact with one or more biological targets and methods for making and using the arrays |
US7429466B2 (en) * | 2000-01-24 | 2008-09-30 | Hypromatrix, Inc | Methods and arrays for detecting biological molecules |
US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
AU2001245988A1 (en) | 2000-03-24 | 2001-10-08 | Biosphere Medical, Inc. | Microspheres for active embolization |
GB0031068D0 (en) * | 2000-12-19 | 2001-01-31 | Smithkline Beecham Plc | Novel compounds |
US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
DE60229118D1 (de) | 2001-04-04 | 2008-11-13 | Nordic Vaccine Technology As | Polynukleotide-bindende komplexe die sterolen und saponine enthalten |
DE10117043A1 (de) * | 2001-04-05 | 2002-11-07 | Gerhard Puetz | Verfahren zur Eliminierung von potentiell toxischen und/oder schädlichen Stoffen |
US20030077829A1 (en) * | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
US20030134423A1 (en) * | 2002-01-04 | 2003-07-17 | Chu Yong Liang | Compounds for delivering substances into cells |
CA2486007C (en) * | 2002-05-15 | 2011-11-22 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
EP2239329A1 (en) * | 2003-03-07 | 2010-10-13 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
CA2488224A1 (en) * | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
US20070179100A1 (en) * | 2003-04-09 | 2007-08-02 | Muthiah Manoharan | Protected monomers |
EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
US8052966B2 (en) | 2003-04-21 | 2011-11-08 | University Of Southern California | Methods and compositions for treating metastatic cancer |
US20070178066A1 (en) * | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
CN100469393C (zh) * | 2003-06-18 | 2009-03-18 | 耶路撒冷希伯来语大学依苏姆研究开发公司 | 用于接种的sphingoid聚烷基胺缀合物 |
AU2004247505B2 (en) * | 2003-06-18 | 2010-01-21 | Biolab Ltd. | Sphingolipids' polyalkylamines conjugates |
US7906122B2 (en) | 2003-06-18 | 2011-03-15 | Yissum Research Development Company Of The Hebrew University Of Jersusalem | Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination |
EP1648519B1 (en) * | 2003-07-16 | 2014-10-08 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
FR2858628B1 (fr) * | 2003-08-04 | 2008-01-04 | Polyplus Transfection | Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines |
US7803397B2 (en) * | 2003-09-15 | 2010-09-28 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
AU2005251403B2 (en) | 2004-06-07 | 2011-09-01 | Arbutus Biopharma Corporation | Cationic lipids and methods of use |
AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
CA2572439A1 (en) * | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory sirna molecules and uses therefor |
WO2006007712A1 (en) * | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
WO2006053430A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
EP3085362B1 (en) | 2005-05-09 | 2021-01-13 | Biosphere Medical, S.A. | Compositions and methods using microspheres and non-ionic contrast agents |
US20060286082A1 (en) * | 2005-06-20 | 2006-12-21 | Kurzweil Raymond C | Systems and methods for generating biological material |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
WO2007070705A2 (en) * | 2005-12-15 | 2007-06-21 | The Trustees Of The University Of Pennsylvania | Cationic lipid-mediated vectors |
JP5364574B2 (ja) | 2006-05-05 | 2013-12-11 | モレキュラー、トランスファー、インコーポレイテッド | 真核細胞のトランスフェクションのための新規試薬 |
US7915399B2 (en) * | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
JP5072275B2 (ja) | 2006-07-03 | 2012-11-14 | テルモ株式会社 | 閉鎖小胞の分離方法、製剤の製造方法および評価方法 |
GB0613753D0 (en) | 2006-07-11 | 2006-08-23 | Norwegian Radium Hospital Res | Method |
JP5080779B2 (ja) | 2006-10-25 | 2012-11-21 | テルモ株式会社 | リポソーム製剤の製造方法 |
AU2007337897A1 (en) * | 2006-12-22 | 2008-07-03 | Imuthes Limited | Lipids and their use as non-viral delivery vehicle |
DE102007015377A1 (de) | 2007-03-28 | 2008-10-02 | Qiagen Gmbh | Verfahren zur Herstellung einer transformierten Zelle |
DE102008016275A1 (de) | 2008-03-28 | 2009-11-19 | Biontex Laboratories Gmbh | Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems |
EP2212425A2 (de) | 2007-11-22 | 2010-08-04 | Biontex Laboratories Gmbh | Verbesserung von transfektionsergebnissen nicht-viraler genliefersysteme durch beeinflussung des angeborenen immunsystems |
DE102008023913A1 (de) | 2008-05-16 | 2009-11-19 | Biontex Laboratories Gmbh | Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems |
DE102007056488A1 (de) | 2007-11-22 | 2009-07-23 | Biontex Laboratories Gmbh | Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems |
CA2910760C (en) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Targeting lipids |
WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
CN102119217B (zh) * | 2008-04-15 | 2015-06-03 | 普洛体维生物治疗公司 | 用于核酸递送的新型制剂 |
US20110223665A1 (en) * | 2008-07-25 | 2011-09-15 | Alnylam Pharmaceuticals, Inc. | ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND |
US8790664B2 (en) | 2008-09-05 | 2014-07-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Multimodular assembly useful for intracellular delivery |
CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
JP6087504B2 (ja) | 2008-11-07 | 2017-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | アミノアルコールリピドイドおよびその使用 |
US8975389B2 (en) | 2009-03-02 | 2015-03-10 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
NZ700688A (en) | 2009-12-01 | 2016-02-26 | Shire Human Genetic Therapies | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
WO2011109427A2 (en) | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Improving the biological activity of sirna through modulation of its thermodynamic profile |
US9102938B2 (en) | 2010-04-01 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | 2′ and 5′ modified monomers and oligonucleotides |
US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
WO2012027675A2 (en) | 2010-08-26 | 2012-03-01 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
EP2691443B1 (en) | 2011-03-28 | 2021-02-17 | Massachusetts Institute of Technology | Conjugated lipomers and uses thereof |
JP6184945B2 (ja) | 2011-06-08 | 2017-08-23 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | mRNA送達のための脂質ナノ粒子組成物および方法 |
AU2012267578B2 (en) | 2011-06-08 | 2017-04-20 | Translate Bio, Inc. | Cleavable lipids |
CN112961855A (zh) | 2011-06-21 | 2021-06-15 | 阿尔尼拉姆医药品有限公司 | 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法 |
KR20140057414A (ko) | 2011-06-22 | 2014-05-12 | 바이옴 바이오사이언스 피브이티. 엘티디. | 컨쥬게이트계 항진균 및 항세균 프로드러그 |
AU2012328570B2 (en) | 2011-10-27 | 2017-08-31 | Massachusetts Institute Of Technology | Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof |
US9796974B2 (en) | 2011-11-18 | 2017-10-24 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
SI3301177T1 (sl) | 2011-11-18 | 2020-07-31 | Alnylam Pharmaceuticals, Inc. | Sredstva RNAi, sestavki in postopki njihove uporabe za zdravljenje s transtiretinom (TTR) povezanih bolezni |
US11073451B2 (en) | 2011-12-19 | 2021-07-27 | Kode Biotech Limited | Biocompatible method of functionalising substrates with inert surfaces |
BR112014024131A2 (pt) | 2012-03-29 | 2017-07-25 | Shire Human Genetic Therapies | lipídios catiônicos ionizáveis |
US9877919B2 (en) | 2012-03-29 | 2018-01-30 | Translate Bio, Inc. | Lipid-derived neutral nanoparticles |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
WO2013166339A1 (en) | 2012-05-02 | 2013-11-07 | Life Technologies Corporation | High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers |
EA201492055A1 (ru) | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
JP6427097B2 (ja) | 2012-06-15 | 2018-11-21 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 癌を処置するための組成物および該組成物を製造するための方法 |
WO2014022739A2 (en) | 2012-08-03 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
CA2884870C (en) | 2012-08-13 | 2022-03-29 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
US10155780B2 (en) | 2012-10-29 | 2018-12-18 | Molecular Transfer, Inc. | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells |
HUE035887T2 (en) | 2012-12-05 | 2018-05-28 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA preparations and methods for their use |
EP2929035A1 (en) | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Lipidic nanoparticles for mrna delivering |
EP2970955B1 (en) | 2013-03-14 | 2018-11-14 | Translate Bio, Inc. | Methods for purification of messenger rna |
CN114015692A (zh) | 2013-03-14 | 2022-02-08 | 阿尔尼拉姆医药品有限公司 | 补体组分C5 iRNA组合物及其使用方法 |
EP2970945B1 (en) | 2013-03-14 | 2024-05-01 | GenVivo, Inc. | Improved thymidine kinase gene |
EA037922B1 (ru) | 2013-03-14 | 2021-06-07 | Шир Хьюман Дженетик Терапис, Инк. | мРНК CFTR И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ МУКОВИСЦИДОЗА У МЛЕКОПИТАЮЩЕГО |
EP3431592A1 (en) | 2013-03-14 | 2019-01-23 | Translate Bio, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
HUE055044T2 (hu) | 2013-03-14 | 2021-10-28 | Translate Bio Inc | MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények |
ES2795249T3 (es) | 2013-03-15 | 2020-11-23 | Translate Bio Inc | Mejora sinérgica de la administración de ácidos nucleicos a través de formulaciones mezcladas |
US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
CN105408481B (zh) | 2013-05-22 | 2021-03-30 | 阿尔尼拉姆医药品有限公司 | SERPINA1 iRNA组合物及其使用方法 |
TW202342750A (zh) | 2013-05-22 | 2023-11-01 | 美商阿尼拉製藥公司 | TMPRSS6 iRNA組成物及其使用方法 |
EP3007709B1 (en) | 2013-06-14 | 2021-12-08 | Akamara Therapeutics, Inc. | Lipid-based platinum compounds and nanoparticles |
TW201610151A (zh) | 2013-09-23 | 2016-03-16 | 阿尼拉製藥公司 | 治療或預防與甲狀腺素運載蛋白相關疾病之方法 |
EP4036241A1 (en) | 2013-10-22 | 2022-08-03 | Translate Bio, Inc. | Cns delivery of mrna and uses thereof |
EP3060257B1 (en) | 2013-10-22 | 2021-02-24 | Translate Bio, Inc. | Lipid formulations for delivery of messenger rna |
ES2954366T3 (es) | 2013-10-22 | 2023-11-21 | Translate Bio Inc | Terapia de ácido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa |
CA2928186A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
CN105814205B (zh) | 2013-12-12 | 2019-11-19 | 阿尔尼拉姆医药品有限公司 | 补体成分iRNA组合物及其使用方法 |
BR112016013516A8 (pt) | 2013-12-12 | 2020-05-19 | Life Technologies Corp | complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula |
WO2015106128A2 (en) | 2014-01-09 | 2015-07-16 | Alnylam Pharmaceuticals, Inc. | MODIFIED RNAi AGENTS |
MY188541A (en) | 2014-01-29 | 2021-12-21 | Vyome Therapeutics Ltd | Besifloxacin for the treatment of resistant acne |
WO2015123264A1 (en) | 2014-02-11 | 2015-08-20 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
TR201900649T4 (tr) | 2014-03-24 | 2019-02-21 | Translate Bio Inc | Oküler hastalıkların tedavisi için mrna tedavisi. |
WO2015153345A1 (en) | 2014-04-03 | 2015-10-08 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
ES2750661T3 (es) | 2014-04-25 | 2020-03-26 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
EP3146049B1 (en) | 2014-05-22 | 2020-02-26 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (agt) irna compositions and methods of use thereof |
JP6557722B2 (ja) | 2014-05-30 | 2019-08-07 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 核酸の送達のための生分解性脂質 |
ES2964588T3 (es) | 2014-06-24 | 2024-04-08 | Translate Bio Inc | Composiciones enriquecidas estereoquímicamente para la administración de ácidos nucleicos |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
CN114146063A (zh) | 2014-07-02 | 2022-03-08 | 川斯勒佰尔公司 | 信使rna的包封 |
WO2016011203A1 (en) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
GB201414464D0 (en) | 2014-08-14 | 2014-10-01 | Technion Res & Dev Foundation | Compositions and methods for therapeutics prescreening |
KR102494171B1 (ko) | 2014-08-20 | 2023-02-02 | 알닐람 파마슈티칼스 인코포레이티드 | 변형 이중-가닥 rna 제제 |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
US20170304459A1 (en) | 2014-10-10 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
EP3207138B1 (en) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
WO2016090262A1 (en) | 2014-12-05 | 2016-06-09 | Shire Human Genetic Therapies, Inc. | Messenger rna therapy for treatment of articular disease |
JP2018504380A (ja) | 2014-12-18 | 2018-02-15 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Reversir(商標)化合物 |
WO2016130806A2 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
WO2016149508A1 (en) | 2015-03-19 | 2016-09-22 | Shire Human Genetic Therapies, Inc. | Mrna therapy for pompe disease |
MX2017012610A (es) | 2015-04-08 | 2018-03-16 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen lect2. |
EP3292201A2 (en) | 2015-05-06 | 2018-03-14 | Alnylam Pharmaceuticals, Inc. | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
CN107847457B (zh) | 2015-05-19 | 2022-07-05 | 阿卡马拉医疗公司 | 制备超分子铂基化合物的方法 |
WO2016196664A1 (en) | 2015-06-01 | 2016-12-08 | Cedars-Sinai Medical Center | Methods and use of compounds that bind to rela of nf-kb |
WO2016201301A1 (en) | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
PL3310764T3 (pl) | 2015-06-19 | 2023-11-06 | Massachusetts Institute Of Technology | Podstawione alkenylem 2,5-piperazynodiony i ich zastosowanie w kompozycjach do dostarczania środka do osobnika lub komórki |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
JP6865207B2 (ja) | 2015-07-13 | 2021-04-28 | ライフ テクノロジーズ コーポレーション | Cho細胞における改善された一過性タンパク質発現のための系及び方法 |
WO2017040078A1 (en) | 2015-09-02 | 2017-03-09 | Alnylam Pharmaceuticals, Inc. | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2017048620A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
US20180312534A1 (en) | 2015-10-16 | 2018-11-01 | Invictus Oncology Pvt. Ltd. | Fluorescent anticancer platinum drugs |
JP2018536689A (ja) | 2015-12-10 | 2018-12-13 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法 |
ES2844180T3 (es) | 2016-04-08 | 2021-07-21 | Translate Bio Inc | Acido nucleico codificante multimérico y usos del mismo |
US20190256845A1 (en) | 2016-06-10 | 2019-08-22 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
CN109312313A (zh) | 2016-06-13 | 2019-02-05 | 川斯勒佰尔公司 | 用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法 |
IL246378A0 (en) | 2016-06-21 | 2016-11-30 | Technion Res & Dev Foundation | A hybrid matrix of polymers that adhere to the mucosa and a lipidic drug release system for the treatment of oral cancer |
CN109562153A (zh) | 2016-08-07 | 2019-04-02 | 诺华股份有限公司 | mRNA介导的免疫方法 |
EP3538136A1 (en) | 2016-11-10 | 2019-09-18 | Translate Bio, Inc. | Subcutaneous delivery of messenger rna |
MA46762A (fr) | 2016-11-10 | 2019-09-18 | Translate Bio Inc | Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm |
TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
KR20230166146A (ko) | 2016-12-16 | 2023-12-06 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법 |
ES2949801T3 (es) | 2017-01-09 | 2023-10-03 | Whitehead Inst Biomedical Res | Métodos para alterar la expresión génica mediante la perturbación de multímeros de factores de transcripción que estructuran bucles reguladores |
MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
EP3592728A1 (en) | 2017-03-07 | 2020-01-15 | Translate Bio, Inc. | Polyanionic delivery of nucleic acids |
TWI801377B (zh) | 2017-04-18 | 2023-05-11 | 美商阿尼拉製藥公司 | 治療具有b型肝炎病毒(hbv)感染之個體之方法 |
US11013905B2 (en) | 2017-05-11 | 2021-05-25 | Tci Llc | Thermal interconnect for implantable blood pump |
IL270631B2 (en) | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr |
WO2018236849A1 (en) | 2017-06-19 | 2018-12-27 | Translate Bio, Inc. | MESSENGER RNA THERAPY FOR THE TREATMENT OF FRIEDREICH ATAXIA |
US11866701B2 (en) | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
EP3727428A1 (en) | 2017-12-20 | 2020-10-28 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
US11597932B2 (en) | 2017-12-21 | 2023-03-07 | Alnylam Pharmaceuticals, Inc. | Chirally-enriched double-stranded RNA agents |
WO2019152802A1 (en) | 2018-02-02 | 2019-08-08 | Translate Bio, Inc. | Cationic polymers |
CA3097912A1 (en) | 2018-05-15 | 2019-11-21 | Translate Bio, Inc. | Subcutaneous delivery of messenger rna |
EP3794008A1 (en) | 2018-05-16 | 2021-03-24 | Translate Bio, Inc. | Ribose cationic lipids |
WO2019226925A1 (en) | 2018-05-24 | 2019-11-28 | Translate Bio, Inc. | Thioester cationic lipids |
WO2019232095A1 (en) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Vitamin cationic lipids |
JP2021525743A (ja) | 2018-05-30 | 2021-09-27 | トランスレイト バイオ, インコーポレイテッド | リン酸エステルカチオン性脂質 |
AU2019277361A1 (en) | 2018-05-30 | 2020-12-17 | Translate Bio, Inc. | Messenger RNA vaccines and uses thereof |
WO2019232208A1 (en) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Cationic lipids comprising a steroidal moiety |
KR20210056331A (ko) | 2018-07-23 | 2021-05-18 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 건조 분말 제형 |
CN112930396B (zh) | 2018-08-24 | 2024-05-24 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
KR20210091120A (ko) | 2018-08-29 | 2021-07-21 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정 |
WO2020056294A1 (en) | 2018-09-14 | 2020-03-19 | Translate Bio, Inc. | Composition and methods for treatment of methylmalonic acidemia |
CN112424355A (zh) | 2018-09-18 | 2021-02-26 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶(KHK)iRNA组合物及其使用方法 |
CN112888451A (zh) | 2018-10-19 | 2021-06-01 | 川斯勒佰尔公司 | 信使rna的无泵包封 |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
US20220016265A1 (en) | 2018-11-09 | 2022-01-20 | Translate Bio, Inc. | Messenger rna therapy for treatment of ocular diseases |
EP3877368A1 (en) | 2018-11-09 | 2021-09-15 | Translate Bio, Inc. | 2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities |
CA3117866A1 (en) | 2018-11-09 | 2020-05-14 | Translate Bio, Inc. | Multi-peg lipid compounds |
EP3876994A2 (en) | 2018-11-09 | 2021-09-15 | Translate Bio, Inc. | Peg lipidoid compounds |
EP3880174A2 (en) | 2018-11-12 | 2021-09-22 | Translate Bio, Inc. | Methods for inducing immune tolerance |
EP3883917B1 (en) | 2018-11-21 | 2024-01-24 | Translate Bio, Inc. | Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna |
AU2019384557A1 (en) | 2018-11-21 | 2021-06-10 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
US20220056444A1 (en) | 2018-12-05 | 2022-02-24 | Empirico Inc. | Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions |
JP2022515744A (ja) | 2018-12-20 | 2022-02-22 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | Kcnt1関連障害の治療のための組成物及び方法 |
CA3125588A1 (en) | 2019-01-07 | 2020-07-16 | Translate Bio, Inc. | Composition and methods for treatment of primary ciliary dyskinesia |
US11116778B2 (en) | 2019-01-15 | 2021-09-14 | Empirico Inc. | Prodrugs of ALOX-15 inhibitors and methods of using the same |
US20220168261A1 (en) | 2019-02-14 | 2022-06-02 | Akamara Therapeutics, Inc. | Compounds and methods for managing cancer through immune system |
US20220177423A1 (en) | 2019-04-18 | 2022-06-09 | Translate Bio, Inc. | Cystine cationic lipids |
US20220233444A1 (en) | 2019-04-22 | 2022-07-28 | Translate Bio, Inc. | Thioester cationic lipids |
WO2020227085A1 (en) | 2019-05-03 | 2020-11-12 | Translate Bio, Inc. | Di-thioester cationic lipids |
CA3140423A1 (en) | 2019-05-14 | 2020-11-19 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
JP2022532652A (ja) | 2019-05-17 | 2022-07-15 | アルニラム ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの経口送達 |
AU2020280105A1 (en) | 2019-05-22 | 2022-01-20 | Massachusetts Institute Of Technology | Circular RNA compositions and methods |
EP3976593A1 (en) | 2019-05-31 | 2022-04-06 | Translate Bio, Inc. | Macrocyclic lipids |
WO2020257611A1 (en) | 2019-06-21 | 2020-12-24 | Translate Bio, Inc. | Cationic lipids comprising an hydroxy moiety |
EP3986858A1 (en) | 2019-06-21 | 2022-04-27 | Translate Bio, Inc. | Tricine and citric acid lipids |
KR20220078557A (ko) | 2019-07-08 | 2022-06-10 | 트랜슬레이트 바이오 인코포레이티드 | 개선된 mrna 로딩된 지질 나노입자 및 이의 제조 방법 |
KR20220038365A (ko) | 2019-07-23 | 2022-03-28 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자의 안정한 조성물 및 제조 방법 |
EP4003397A1 (en) | 2019-07-30 | 2022-06-01 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr |
EP4013870A1 (en) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof |
CA3155003A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
EP4041400A1 (en) | 2019-10-09 | 2022-08-17 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
JP2022553042A (ja) | 2019-10-21 | 2022-12-21 | トランスレイト バイオ, インコーポレイテッド | メッセンジャーrnaの組成物、方法および使用 |
WO2021087036A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
US20230056569A1 (en) | 2019-11-22 | 2023-02-23 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
CA3160739A1 (en) | 2019-12-04 | 2021-06-10 | Brian Goodman | Circular rna compositions and methods |
IL293824A (en) | 2019-12-13 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them |
WO2021127641A1 (en) | 2019-12-20 | 2021-06-24 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
CN115515559A (zh) | 2019-12-20 | 2022-12-23 | 翻译生物公司 | 信使rna的直肠递送 |
WO2021142245A1 (en) | 2020-01-10 | 2021-07-15 | Translate Bio, Inc. | Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
WO2021173840A1 (en) | 2020-02-25 | 2021-09-02 | Translate Bio, Inc. | Improved processes of preparing mrna-loaded lipid nanoparticles |
EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
EP4127168A1 (en) | 2020-03-26 | 2023-02-08 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
EP4133076A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof |
WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
CA3181400A1 (en) | 2020-04-27 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein e (apoe) irna agent compositions and methods of use thereof |
US20230190954A1 (en) | 2020-05-07 | 2023-06-22 | Translate Bio, Inc. | Composition and methods for treatment of primary ciliary dyskinesia |
US20230181619A1 (en) | 2020-05-07 | 2023-06-15 | Translate Bio, Inc. | Improved compositions for cftr mrna therapy |
CA3177940A1 (en) | 2020-05-07 | 2021-11-11 | Anusha DIAS | Optimized nucleotide sequences encoding sars-cov-2 antigens |
US20230226219A1 (en) | 2020-05-14 | 2023-07-20 | Translate Bio, Inc. | Peg lipidoid compounds |
WO2021231691A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi) |
EP4150076A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
JP2023526284A (ja) | 2020-05-15 | 2023-06-21 | トランスレイト バイオ, インコーポレイテッド | mRNA送達のための脂質ナノ粒子製剤 |
WO2021231675A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
EP4150078A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
WO2021231685A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
CN116322788A (zh) | 2020-05-19 | 2023-06-23 | 奥纳治疗公司 | 环状rna组合物和方法 |
AR122534A1 (es) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |
WO2021252557A1 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
WO2022006527A1 (en) | 2020-07-02 | 2022-01-06 | Maritime Therapeutics, Inc. | Compositions and methods for reverse gene therapy |
JP2023540429A (ja) | 2020-07-10 | 2023-09-25 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | てんかんを治療するための方法及び組成物 |
EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
JP2023544413A (ja) | 2020-10-05 | 2023-10-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法 |
KR20230087536A (ko) | 2020-10-12 | 2023-06-16 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자를 제조하는 개선된 프로세스 |
US20220133631A1 (en) | 2020-10-12 | 2022-05-05 | Translate Bio, Inc. | Process of preparing ice-based lipid nanoparticles |
EP4232581A1 (en) | 2020-10-21 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
EP4240326A1 (en) | 2020-11-09 | 2023-09-13 | Translate Bio, Inc. | Improved compositions for delivery of codon-optimized mrna |
CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
MX2023006133A (es) | 2020-11-25 | 2023-07-18 | Translate Bio Inc | Formulaciones estables de nanopartículas de lipídos líquidos. |
AU2021393417A1 (en) | 2020-12-01 | 2023-06-29 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
JP2024504614A (ja) | 2021-01-14 | 2024-02-01 | トランスレイト バイオ, インコーポレイテッド | mRNAがコードする抗体を送達する方法および組成物 |
BR112023015761A2 (pt) | 2021-02-12 | 2023-11-07 | Alnylam Pharmaceuticals Inc | Superóxido dismutase 1 (sod1) composições de irna e métodos de uso das mesmas para tratar ou prevenir doenças neurodegenerativas associadas a superóxido dismutase 1 (sod1) |
JP2024509783A (ja) | 2021-02-25 | 2024-03-05 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | プリオンタンパク質(prnp)irna組成物およびその使用方法 |
EP4305169A1 (en) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
WO2022204549A1 (en) | 2021-03-25 | 2022-09-29 | Translate Bio, Inc. | Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof |
CN117203336A (zh) | 2021-03-29 | 2023-12-08 | 阿尔尼拉姆医药品有限公司 | 亨廷顿蛋白(HTT)iRNA药剂组合物以及其使用方法 |
JP2024515668A (ja) | 2021-04-19 | 2024-04-10 | トランスレイト バイオ, インコーポレイテッド | Mrnaの送達のための改善された組成物 |
EP4330396A1 (en) | 2021-04-29 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
EP4341405A1 (en) | 2021-05-20 | 2024-03-27 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
AU2022283796A1 (en) | 2021-06-04 | 2023-11-09 | Alnylam Pharmaceuticals, Inc. | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
EP4363574A1 (en) | 2021-06-29 | 2024-05-08 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
WO2023278754A1 (en) | 2021-07-01 | 2023-01-05 | Translate Bio, Inc. | Compositions for delivery of mrna |
TW202325312A (zh) | 2021-07-23 | 2023-07-01 | 美商艾拉倫製藥股份有限公司 | β-鏈蛋白(CTNNB1)iRNA組成物及其使用方法 |
WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
TW202334080A (zh) | 2021-11-08 | 2023-09-01 | 美商歐納醫療公司 | 用於遞送環狀聚核苷酸之脂質奈米粒子組合物 |
WO2023086893A1 (en) | 2021-11-10 | 2023-05-19 | Translate Bio, Inc. | Composition and methods for treatment of primary ciliary dyskinesia |
WO2023122762A1 (en) | 2021-12-22 | 2023-06-29 | Camp4 Therapeutics Corporation | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023214405A1 (en) | 2022-05-01 | 2023-11-09 | Yeda Research And Development Co. Ltd. | Reexpression of hnf4a to alleviate cancer-associated cachexia |
WO2023240277A2 (en) | 2022-06-10 | 2023-12-14 | Camp4 Therapeutics Corporation | Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
WO2024102730A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and nanoparticle compositions for delivering polynucleotides |
WO2024102677A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Circular rna compositions |
WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
WO2024112652A1 (en) | 2022-11-21 | 2024-05-30 | Translate Bio, Inc. | Compositions of dry powder formulations of messenger rna and methods of use thereof |
WO2024119145A1 (en) | 2022-12-01 | 2024-06-06 | Camp4 Therapeutics Corporation | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas |
WO2024126809A1 (en) | 2022-12-15 | 2024-06-20 | Sanofi | Mrna encoding influenza virus-like particle |
WO2024129982A2 (en) | 2022-12-15 | 2024-06-20 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
WO2024133515A1 (en) | 2022-12-20 | 2024-06-27 | Sanofi | Rhinovirus mrna vaccine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3869273A (en) * | 1971-04-29 | 1975-03-04 | Dow Chemical Co | Compositions and method for altering plant growth with an alkylenebisdithiocarbamatic complex |
US4324683A (en) * | 1975-08-20 | 1982-04-13 | Damon Corporation | Encapsulation of labile biological material |
FR2645866B1 (fr) * | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
-
1989
- 1989-04-17 FR FR898905037A patent/FR2645866B1/fr not_active Expired - Fee Related
-
1990
- 1990-04-12 CA CA002014518A patent/CA2014518C/fr not_active Expired - Lifetime
- 1990-04-12 IL IL9407790A patent/IL94077A/en not_active IP Right Cessation
- 1990-04-13 DK DK90401020.4T patent/DK0394111T3/da active
- 1990-04-13 EP EP90401020A patent/EP0394111B1/fr not_active Expired - Lifetime
- 1990-04-13 AT AT90401020T patent/ATE154035T1/de not_active IP Right Cessation
- 1990-04-13 ES ES90401020T patent/ES2104593T3/es not_active Expired - Lifetime
- 1990-04-13 DE DE69030839T patent/DE69030839T2/de not_active Expired - Lifetime
- 1990-04-17 JP JP2099472A patent/JP2716565B2/ja not_active Expired - Lifetime
- 1990-04-17 US US07/509,788 patent/US5171678A/en not_active Expired - Lifetime
-
1994
- 1994-02-03 US US08/191,068 patent/US5476962A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/477,690 patent/US5616745A/en not_active Expired - Lifetime
-
1997
- 1997-06-05 GR GR970400306T patent/GR3023691T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
FR2645866B1 (fr) | 1991-07-05 |
GR3023691T3 (en) | 1997-09-30 |
DE69030839D1 (de) | 1997-07-10 |
ATE154035T1 (de) | 1997-06-15 |
ES2104593T3 (es) | 1997-10-16 |
EP0394111A1 (fr) | 1990-10-24 |
DK0394111T3 (da) | 1997-09-08 |
IL94077A0 (en) | 1991-01-31 |
CA2014518C (fr) | 2003-11-18 |
US5171678A (en) | 1992-12-15 |
DE69030839T2 (de) | 1997-11-20 |
US5476962A (en) | 1995-12-19 |
US5616745A (en) | 1997-04-01 |
IL94077A (en) | 1994-12-29 |
EP0394111B1 (fr) | 1997-06-04 |
JPH02292246A (ja) | 1990-12-03 |
FR2645866A1 (fr) | 1990-10-19 |
CA2014518A1 (fr) | 1990-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2716565B2 (ja) | 新規リポポリアミン、その製造方法及び利用 | |
US6291673B1 (en) | Folic acid derivatives | |
WO2002004936A1 (en) | Probe for mass spectrometry of liquid sample | |
Kopple et al. | Reactivity of Cyclic Peptides. II. cyclo-L-Tyrosyl-L-histidyl and cyclo-L-Tyrosyltriglycyl-L-histidylglycyl | |
EP0034238A1 (en) | Pharmacologically active amine-carboxyboranes | |
EP0181721B1 (en) | Esters of boron analogues of amino acids | |
WO1989008115A1 (fr) | NOUVEAUX DERIVES DE LA DEOXY-2'-URIDINE SUBSTITUEE EN POSITION 5, 3' ou 5' PAR DES GROUPEMENTS alpha-AMINO ACYLES, PROCEDE POUR LEUR OBTENTION ET MEDICAMENTS LES CONTENANT | |
Pickersgill et al. | Preparation of functionalized, conformationally constrained DTPA analogues from L-or D-serine and trans-4-hydroxy-L-proline. Hydroxymethyl substituents on the central acetic acid and on the backbone | |
Barišić et al. | Ferrocene compounds: Part XXXIII. Synthesis and characterization of amino acids containing skeletal 1, 1′-ferrocenylene unit | |
JPS61155346A (ja) | 9―(1,3―ジヒドロキシ―2―プロポキシメチル)グアニン類化合物の製法 | |
WO2006070737A1 (ja) | ベンゼン環上に二置換基を有するβ-ベンジルオキシアスパラギン酸誘導体 | |
JP4442864B2 (ja) | リン脂質誘導体及び遺伝子導入キャリア | |
BG64597B1 (bg) | Метод за синтез на хлоропуринови междинни съединения | |
JPH0426699A (ja) | アミノ酸誘導体及びその製造法 | |
Taketomi et al. | New approach for characterization of lysosulfatide by TLC, fast atom bombardment mass spectrometry and NMR spectroscopy | |
JPH03188088A (ja) | 新規リゾホスファチジルセリン | |
US5023513A (en) | Amine-alkylborane derivatives and methods | |
JPH02250898A (ja) | ガストリン放出ペプチド拮抗質 | |
US20040101839A1 (en) | Novel functional peptide nucleic acid monomer and process for producing the same | |
Ruani et al. | Synthesis of sphingosine conjugate with controlled pore glass beads | |
JP3404787B2 (ja) | 新規ジエチレントリアミンペンタ酢酸誘導体、該誘導体と金属原子との錯化合物、及び該錯化合物を含む診断剤 | |
Riggio et al. | Specific ligands for the affinity chromatography of cholinergic proteins | |
Huang et al. | Synthesis Of A New Series Of Cyclic Pseudopeptides Containing Pyridine As Backbone Modifier | |
Civitello et al. | Synthesis of Peptide− Oligonucleotide Conjugates for Chromium Coordination | |
JP3500187B2 (ja) | 新規なクモ毒誘導体及びその製造法、並びにそれを含有するグルタミン酸レセプター遮断剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071107 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081107 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081107 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091107 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101107 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101107 Year of fee payment: 13 |